Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Inclusion Criteria: * Newly diagnosed, histologically proven single supratentorial GBM (WHO grade 4); * EGFR positive; * \>50％ of the gross tumor volume removed by surgery； * Karnofsky performance score (KPS) ≥ 60; * Adequate renal function (creatinine ≤1.5×upper limit of normal \[ULN\] or creatinine clearance ≥ 60 mL/min), hepatic function (total bilirubin ≤1.5×ULN and serum transaminases ≤3×ULN), and hematologic function (white blood cell count ≥ 3,000/uL or absolute neutrophil count ≥ 1,500/uL, platelets ≥ 100,000/uL, and hemoglobin ≥ 10 g/dL). * Tumor tissue was required for central pathology review and re-checking EGFR and MGMT expression status; * An interval of 2 to 6 weeks between surgery and RT was required. Exclusion Criteria: * Negative EGFR expression; * Prior chemotherapy, anti-EGFR therapy, RT, or a history of malignancy in the previous 5 years; * Patients with severe complications or active infection; * Continuous vomiting that could interfere with the oral administration of TMZ; * Pregnancy